The TRITON versus PLATO trials: Differences beyond platelet inhibition

Thrombosis and Haemostasis

Volumn 103, Issue 2, 2010, Pages 259-261

  Serebruany, Victor L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; Clopidogrel; Outcomes; Prasugrel; Ticagrelor

Indexed keywords

CLOPIDOGREL; EFFIENT; FIBRINOGEN RECEPTOR; PRASUGREL; TICAGRELOR; TICLOPIDINE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; AGITATION; ARRHYTHMOGENESIS; BLEEDING; CANCER RISK; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; MORTALITY; OUTCOME ASSESSMENT; PANIC; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PURINE METABOLISM; REVIEW; SIDE EFFECT; STENT THROMBOSIS; TREATMENT WITHDRAWAL; URIC ACID BLOOD LEVEL;

ACUTE CORONARY SYNDROME; ADENOSINE; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 75749101040     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-10-0695     Document Type: Review

References (19)

1. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
2. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
3. The FDA Prasugrel Secondary Review. Available for download at http://www.fda. gov/ohrms/dockets/ac/09/briefing/2009-4412b1-00-FDA.htm
4. The FDAA Prasugrel Action Package. Available for download at http://www.ac cessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseacti
5. Serebruany VL, Atar D. The PLATO trial: Do you believe in magic? Eur Heart J 2009; in press.
6. CURRENT Investigators: A 2X2 Factorial Randomized Trial of Optimal Clopidogrel and Aspirin Dosing in Patients with ACS Undergoing an Early Invasive Strategy with Intent For PCI (OASIS-7 trial). Presented at European College of Cardiology Meeting, Barcelona, August 30, 2009.
7. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203-2216.
8. Serebruany V. Excess rates of nonfatal myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel: preventing clinical events or chasing enzymatic ghosts? Am J Cardiol 2008; 101: 1364-1366.
9. Serebruany V. The FDA Prasugrel Review: Adjudication of myocardial infarction controversy. Cardiology 2009; 114: 126-129.
10. Thygesen K, Alpert JS, White HD on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007; 28: 2525-2538.
11. Stolt Steiger V, Goy JJ, et al. Significant decrease in in-hospital mortality and major adverse cardiac events in Swiss STEMI patients between 2000 and December 2007. Swiss Med Wkly 2009; 139: 453-457.
12. Kulik A, Chan V, Ruel M. Antiplatelet therapy and coronary artery bypass graft surgery: perioperative safety and efficacy. Expert Opin Drug Saf 2009; 8: 169-182.
13. Serebruany VL. Prasugrel and cancer risks: Potential causes and implications. Am J Med 2009; 122: 407-408.
14. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet 1996; 348: 1329-1339.
15. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. N Engl J Med 2006; 354: 1706-1717.
16. Serebruany VL, Stebbing J, Atar D. Dyspnea after antiplatelet agents: the AZD6140 controversy. Int J Clin Pract 2007; 61: 529-533.
17. Stark U, Brodmann M, Lueger A, Stark G. Antiarrhythmic effects of adenosine on ischemia-induced ventricular fibrillation. J Crit Care 2001; 16: 8-16.
18. Stutzmann GE, Marek GJ, Aghajanian GK. Adenosine preferentially suppresses serotonin2A receptor-enhanced excitatory postsynaptic currents in layer V neurons of the rat medial prefrontal cortex. Neuroscience 2001; 105: 55-69.
19. Amorini AM, Petzold A, Tavazzi B, et al. Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin Biochem. 2009; 42: 1001-1006.